Guidance on GxP data integrity

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued comprehensive guidance regarding the implementation of compliant data governance systems across all GxP sectors, including laboratory, clinical, manufacturing, distribution, and pharmacovigilance practices. This guidance was developed to address recurring fundamental failures identified by the MHRA and international regulatory partners during routine inspections, which have frequently resulted in formal regulatory actions. Under the current regulatory framework, the MHRA clarifies that the 2021 OECD Advisory Document on Data Integrity now takes precedence for Good Laboratory Practice (GLP) facilities due to the United Kingdom's membership in the OECD Mutual Acceptance of Data System. Organizations are required to adopt these international standards while continuing to use the 2018 MHRA GXP Data Integrity Guidance as a supplemental resource to foster a strong internal data integrity culture. While the document does not name a specific company or individual inspection dates as it is a general regulatory resource, it mandates that all GxP-regulated entities establish robust governance systems and review additional guidance related to good practice during the COVID-19 pandemic. The primary required action for facilities is the alignment of their data management systems with these updated standards to ensure the accuracy and reliability of all regulatory data.